Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 8Breast 3Gastrointestinal 2Thoracic 1Sarcoma 1Gynecologic 1CNS 1

Conditions

Breast Neoplasms 96Inflammatory Breast Neoplasms 9Carcinoma, Intraductal, Noninfiltrating 8Breast Neoplasms, Male 6Breast Carcinoma In Situ 6Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Neoplasms 3Locally Advanced Breast Cancer 2Colorectal Neoplasms 2Breast Cancer Patients 2Stress, Psychological 1Postoperative Complications 1Pathologic Complete Response 1Neovascularization, Pathologic 1Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer 1Motor Activity 1Margins of Excision 1Inflammation 1Infertility 1High-Risk Cancer 1Head and Neck Neoplasms 1HER2-positive Breast Cancer 1Evaluation of the Value of Mammaprint Test Gene Variation in the Prediction of Neoadjuvant Chemotherapy for Breast Cancer 1Colonic Neoplasms 1Cardiotoxicity 1Carcinoma, Lobular 1Breast Cancer-specific Survival 1Breast Cancer Metastatic 1Breast Cancer Invasive 1

Interventions

Paclitaxel 26pembrolizumab 24Docetaxel 20Capecitabine 19Fulvestrant 17Trastuzumab 16Anastrozole 15Cyclophosphamide 14Lapatinib 13Letrozole 11Carboplatin 11Radiotherapy 10Doxorubicin 10palbociclib 9Therapeutics 9Nivolumab 9Exercise 9Gemcitabine 8Cisplatin 8Blood Specimen Collection 8Tamoxifen 7Bevacizumab 7liposomal doxorubicin 6exemestane 6abemaciclib 6Vinorelbine 6Standard of Care 6Fluorouracil 6atezolizumab 5Surveys and Questionnaires 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × Neoadjuvant Therapy × Breast × Clear all
NCT06739655 2026-02-04

PRADAIIBE

Cancer Research Antwerp

Phase NA Recruiting
180 enrolled
Breast

Breast Neoplasms, Neoplasms

NCT05912062 2023-09-29

BiOnHER

Institut Català d'Oncologia

Unknown
80 enrolled
Breast

Breast Neoplasms, Neoplasms

NCT00491816 2017-01-19

Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer

University of Kansas Medical Center

Phase 2 Unknown
32 enrolled
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡